Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796116 | 0.90 | FABP3 (0.37) | CHRM2CHRM3ADRA1AADRA1BCYP1A2 | |
| SCHEMBL24796305 | 0.85 | HPGD (0.40) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL24796396 | 0.79 | SMN1; SMN2 (0.33) | TSHRSMN1; SMN2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL21389277 | 0.73 | GAA (0.38) | ALDH1A1 | |
| SCHEMBL21389249 | 0.72 | HSD17B10 (0.53) | TSHRSMN1; SMN2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL21389498 | 0.72 | KMT2A (0.36) | CYP1A2CYP2C19TSHRHSD17B10ALDH1A1 | |
| SCHEMBL24796307 | 0.71 | HPGD (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL21389312 | 0.70 | ALDH1A1 (0.34) | TSHRSMN1; SMN2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL21389449 | 0.70 | ALDH1A1 (0.34) | TSHRSMN1; SMN2HSD17B10ALDH1A1KDM4E | |
| SCHEMBL24796301 | 0.70 | HSD17B10 (0.35) | SMN1; SMN2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | CHRM2 781/4885CHRM3 510/4885ADRA1A 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.